REED ELIZABETH E
SEC CIK 1283303 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | SVP, GC, Corp. Sec | 142.9K | — | $8.33M | 46 | 2021-08-13 | 2026-09-15 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 46
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 21:32 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $15.46 | +37.5K | 142.9K | +36% | +$579.8K |
| DMT | 2026-09-17 21:32 | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $62.34 | -37.5K | 105.4K | -26% | -$2.34M |
| DMT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $14.81 | +24.2K | 109.5K | +28% | +$359.2K |
| DMT | 2026-05-06 20:00 | 2026-05-04+ | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $45.06 | -24.2K | 105.2K | -19% | -$1.09M |
| DT | 2026-04-15 21:47 | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | A - Grant | $0.00 | +14.0K | 119.2K | +13% | $0 |
| DMT | 2026-04-15 21:47 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $17.76 | +37.5K | 156.7K | +31% | +$666.0K |
| DMT | 2026-04-15 21:47 | 2026-04-14+ | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $41.29 | -51.5K | 105.2K | -33% | -$2.13M |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $15.46 | +10.0K | 115.2K | +10% | +$154.6K |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $30.00 | -10.0K | 105.2K | -9% | -$300.0K |
| D | 2026-03-18 | 2026-03-16 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $19.08 | +10.0K | 115.2K | +10% | +$190.8K |
| D | 2026-03-18 | 2026-03-16 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $28.09 | -10.0K | 105.2K | -9% | -$280.9K |
| DM | 2026-02-19 | 2026-02-17 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $27.83 | -10.0K | 109.5K | -8% | -$278.3K |
| D | 2026-02-19 | 2026-02-17 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $19.08 | +10.0K | 115.2K | +10% | +$190.8K |
| M | 2026-02-05 | 2026-02-04 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale | $32.18 | -2,994 | 105.7K | -3% | -$96.4K |
| D | 2026-02-03 | 2026-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | A - Grant | $0.00 | +25.1K | 115.4K | +28% | $0 |
| D | 2026-02-03 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale | $32.12 | -7,175 | 108.2K | -6% | -$230.5K |
| D | 2026-01-21 | 2026-01-20 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $27.34 | -10.0K | 90.3K | -10% | -$273.4K |
| D | 2026-01-21 | 2026-01-20 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $19.08 | +10.0K | 100.3K | +11% | +$190.8K |
| D | 2025-09-24 | 2025-09-22 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $25.00 | -10.0K | 89.9K | -10% | -$250.0K |
| D | 2025-09-24 | 2025-09-22 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | $19.08 | +10.0K | 99.9K | +11% | +$190.8K |
| D | 2025-05-05 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | S - Sale+OE | $21.05 | -4,920 | 89.5K | -5% | -$103.6K |
| D | 2025-05-05 | 2025-05-02 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | CLO, GC | M - OptEx | — | +4,920 | 94.4K | +5% | — |
| D | 2025-02-12 | 2025-02-12 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale+OE | $23.53 | -8,000 | 89.5K | -8% | -$188.2K |
| D | 2025-02-12 | 2025-02-10 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | M - OptEx | — | +8,000 | 97.5K | +9% | — |
| D | 2025-02-04 | 2025-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +21.5K | 98.4K | +28% | $0 |
| D | 2025-02-04 | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $19.78 | -8,951 | 89.5K | -9% | -$177.1K |
| 2025-01-23 | 2025-01-22 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $19.46 | -2,437 | 76.9K | -3% | -$47.4K | |
| 2024-09-09 | 2024-09-09 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $11.52 | -4,387 | 78.6K | -5% | -$50.5K | |
| 2024-09-09 | 2024-09-05 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +6,750 | 83.0K | +9% | $0 | |
| D | 2024-02-02 | 2024-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +25.0K | 81.0K | +45% | $0 |
| DM | 2024-02-02 | 2024-02-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $8.71 | -4,764 | 78.9K | -6% | -$41.5K |
| 2024-01-25 | 2024-01-23 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $8.96 | -2,062 | 56.0K | -4% | -$18.5K | |
| 2023-09-05 | 2023-08-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +3,300 | 59.9K | +6% | $0 | |
| 2023-09-05 | 2023-09-05 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $14.71 | -1,815 | 58.1K | -3% | -$26.7K | |
| 2023-05-12 | 2023-05-10 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $16.59 | -825 | 56.6K | -1% | -$13.7K | |
| D | 2023-02-02 | 2023-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +20.2K | 60.0K | +51% | $0 |
| D | 2023-02-02 | 2023-02-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $22.25 | -2,590 | 57.4K | -4% | -$57.6K |
| 2023-01-26 | 2023-01-24 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $21.50 | -2,062 | 39.8K | -5% | -$44.3K | |
| M | 2022-05-12 | 2022-05-10+ | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $21.51 | -1,950 | 42.9K | -4% | -$41.9K |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +9,840 | 45.1K | +28% | $0 |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $27.40 | -1,350 | 43.8K | -3% | -$37.0K |
| 2022-01-26 | 2022-01-24 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $24.98 | -2,250 | 35.3K | -6% | -$56.2K | |
| 2022-01-12 | 2022-01-10 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +5,000 | 42.5K | +13% | $0 | |
| 2022-01-12 | 2022-01-11 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $27.40 | -5,000 | 37.5K | -12% | -$137.0K | |
| 2021-08-17 | 2021-08-17 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | S - Sale | $17.12 | -1,407 | 37.5K | -4% | -$24.1K | |
| 2021-08-17 | 2021-08-13 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | SVP, GC, Corp. Sec | A - Grant | $0.00 | +4,500 | 39.0K | +13% | $0 |
Purchase Sale Sale after option exercise All abbreviations